<DOC>
	<DOCNO>NCT02485327</DOCNO>
	<brief_summary>Primary Objective : To characterize within-subject variability systemic exposure pharmacokinetic ( PK ) insulin replicate single dose Afrezza inhale Technosphere Insulin ( TI ) T1DM patient euglycemic clamp setting . To characterize within-subject variability metabolic activity ( pharmacodynamic [ PD ] ) replicate single dose Afrezza inhale TI T1DM patient euglycemic clamp setting . Secondary Objectives : To assess PK characteristic replicate single dose Afrezza inhale TI euglycemic clamp set . To assess PD characteristic replicate single dose Afrezza inhale TI euglycemic clamp set . To assess safety tolerability replicate single dose Afrezza inhale TI euglycemic clamp setting .</brief_summary>
	<brief_title>PK PD Within-Subject Variability Single Dose Afrezza Inhaled Technosphere Insulin Patients With Diabetes Mellitus Type 1 ( T1DM )</brief_title>
	<detailed_description>The maximum study duration per patient approximately 9 week ( screen 3 28 Days , treatment period 2 day [ Periods 1 2 ] , washout period 5 19 day [ treatment period ] , end-of-study visit 7 14 day study drug administration Period 2 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Body weight 50 95 kg , inclusive , body mass index 18.5 29 kg/m² , inclusive . Fasting serum Cpeptide &lt; 0.3 nmol/L . Glycohemoglobin ( HbA1c ) ≤75 mmol/mol ( ≤9 % ) . Stable insulin regimen least 2 month prior study ( respect safety patient scientific integrity study ) . Certified otherwise healthy T1DM patient assessment medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , unless Investigator considers abnormality clinically irrelevant interfere conduct study ( respect safety subject scientific integrity study ) . Normal vital sign least 10 minute rest supine position : 95 mmHg &lt; systolic blood pressure ( SBP ) &lt; 150 mmHg . 45 mmHg &lt; diastolic blood pressure ( DBP ) &lt; 95 mmHg . 50 bpm &lt; heart rate ( HR ) &lt; 90 bpm . Normal standard 12lead electrocardiogram ( ECG ) least 10 minute rest supine position ; 120 m &lt; PR &lt; 220 m , QRS &lt; 120 m , QTc ≤450 m male , ≤470 m female . Laboratory parameter within normal range ( define screen threshold Investigator site ) , unless Investigator considers abnormality clinically irrelevant diabetes patient ; however serum creatinine strictly upper laboratory norm ; alkaline phosphatase , hepatic enzyme ( aspartate aminotransferase , alanine aminotransferase ) , total bilirubin ( unless patient document Gilbert syndrome ) 1.5 x upper limit normal ( ULN ) . Women childbearing potential ( less 2 year postmenopausal surgically sterile 3 month ) , must negative serum betahuman chorionic gonadotropin ( βHCG ) pregnancy test screen negative urine βHCG pregnancy test Day 1 treatment period ( TPs ) must use highly effective method birth control , define result low failure rate ( ie , le 1 % per year ) accord Note guidance nonclinical safety study conduct human clinical trial pharmaceutical ( CPMP/ICH/286/95 , modification ) . During entire study female subject childbearing potential must use 2 independent method contraception , eg , diaphragm spermicidecoated condom . The use condom spermicidal cream sufficiently reliable . For postmenopausal woman presence less 2 year post menopausal , surgically sterile 3 month , hormonal status determine ( folliclestimulating hormone [ FSH ] &gt; 30 IU/L ) . Having give write informed consent prior undertake studyrelated procedure . Covered health insurance system applicable , and/or compliance recommendation national ( German ) law force relate biomedical research . Not administrative legal supervision . Nonsmoking least last 6 month screen ( confirm serum cotinine &lt; 25 µg/L urine &lt; 500 µg/L ) . Pulmonary function test screening : forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) great equal 70 % individual prediction accord equation Third National Health Nutrition Examination Survey ( NHANES III ) . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart T1DM ) , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Severe hypoglycemia result coma/seizures require assistance another person , and/or hospitalization diabetic ketoacidosis last 6 month screen visit . Frequent headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Blood donation , volume , within 3 month inclusion . Symptomatic postural hypotension , irrespective decrease blood pressure , asymptomatic postural hypotension define decrease systolic blood pressure ≥20 mmHg within 3 minute change supine stand position . Presence history drug hypersensitivity , allergic disease diagnose treated physician . Likelihood require treatment study period drug permit clinical study protocol . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) . Excessive consumption beverage contain xanthine base ( 4 cup glass per day ) . If female , pregnancy ( define positive βHCG blood test ) , breastfeed screen treatment period ( define positive βHCG urine test ) . Any medication ( include St John 's Wort ) within 14 day inclusion within 5 time elimination halflife PD halflife medication , exception insulin , stable treatment ( least 2 month ) thyroid hormone , lipidlowering antihypertensive drug female exception hormonal contraception menopausal hormone replacement therapy . Any vaccination within last 28 day . Any patient , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . Any patient exclusion period previous study accord applicable regulation . Any patient contact case emergency . Any patient Investigator subInvestigator , research assistant , pharmacist , study coordinator , staff thereof , directly involve conducting study . Positive result follow test : hepatitis B surface antigen ( HBs Ag ) , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) . Positive result urine drug screen ( amphetamines/methamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates , cotinine ) . Positive alcohol test . Presence history acute chronic obstructive bronchopulmonary disease ( COPD ) include asthma , cancer . Upper respiratory tract infection within 8 week screen . Known hypersensitivity Afrezza TI excipients . Inability , opinion Principal Investigator designee , adequately inhale Afrezza powder . Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis firstdegree relative ( parent , sibling , child ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>